Clinical Trial Update: Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating Avonex (Interferon-beta-1a) with or without methylprednisolone for relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)
• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Biogen | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED